Article

Covance, CORL collaborate for ocular drug development

Covance and Comparative Ophthalmic Research Laboratories (CORL) announce their collaboration as a resource for ocular drug development.

Covance and Comparative Ophthalmic Research Laboratories (CORL) announce their collaboration as a resource for ocular drug development.

Covance provides testing services for the pharmaceutical and biotechnology industries. CORL is a collaborative team of internationally recognized vision scientists providing world-class vision research support for industry.

Having worked together for the past 10 years, the Covance/CORL alliance brings an unprecedented breadth of expertise and depth of knowledge to ocular drug development, the organizations said in a prepared joint statement.

Through the collaboration, the organizations are able to provide advanced ophthalmic techniques and complex study designs, Good Laboratory Practice-compliant studies, and close proximity for maximum study responsiveness.

For more information, visit Covance at Booth 614.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.